|View printer-friendly version|
|Abeona Therapeutics Appoints Christine Silverstein as Vice President of Investor Relations|
Silverstein brings more than 12 years of experience in the corporate communications and financial services industries, spending the majority of her career providing a full range of investor relations and public relations strategy and counsel to life sciences companies. Her most recent roles include Director of Investor Relations at
"It's an exciting time to be joining Abeona," said Mrs. Silverstein. "With the Company's commitment to developing treatments for rare diseases and the breadth of its diverse product portfolio coupled with its strong scientific expertise, I see tremendous potential for the company. I look forward to conveying the value proposition of the company to a diverse network of institutional and retail investors and further broadening its reach within the investment community."
Earlier in her career, Silverstein served as Managing Director at
"We are very pleased to have Christine join our team," said
About Abeona: Abeona Therapeutics Inc. develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). We are also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, management plans for the Company, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Company and Media Contacts: